전자 피부 패치 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2025-2030년)

The electronic skin patch market is valued at USD 16.19 billion in 2025 and is forecast to reach USD 31.56 billion by 2030, reflecting a 14.28% CAGR over 2025-2030.

Sensing and Diagnostic Patches hold the largest 46% revenue share in 2024, while Energy-Harvesting Smart Patches, enabled by battery-less power architectures, post the strongest 21.8% CAGR outlook. Cardiovascular Monitoring leads all applications at 38.2% share, but Women's Health and Fertility registers the fastest 19.51% CAGR as at-home breast ultrasound and hormone tracking patches attract new users. Regionally, North America commands 37.9% share, backed by FDA clearance of over-the-counter continuous glucose monitors (CGMs) from Dexcom and Abbott in 2024, whereas Asia Pacific accelerates at 16.5% CAGR underpinned by large-scale electronics manufacturing and supportive innovation programs. Investment momentum remains high: VitalConnect and Biolinq each secured USD 100 million rounds in 2025 to expand high-volume manufacturing and regulatory submissions, illustrating how funding channels reward platforms that blend clinically validated sensors with consumer-grade usability.

Global Electronic Skin Patches Market Trends and Insights

Continuous Glucose-Monitoring (CGM) Patch Adoption Surge

FDA clearance of Dexcom Stelo and Abbott Lingo in 2024 removed prescription barriers and opened the CGM category to 25 million U.S. type 2 diabetics not on insulin, while also legitimizing consumer-grade biosensing for preventive metabolic health. Disposable, all-in-one designs such as Dexcom's Simplera lower training costs for payers and providers, fostering rapid uptake in pharmacy channels. Dexcom projects USD 40 million first-year revenue from Stelo, signaling strong elasticity in the newly addressable segment. Pharmaceutical firms are now embedding CGM data streams into weight-loss and metabolic-syndrome programs, expanding device demand beyond the core diabetes cohort. Growth is global, yet North America captures early volumes due to favorable reimbursement. Vendors are racing to integrate glucose telemetry into closed-loop therapy ecosystems, accelerating replacement of finger-stick meters in home settings.

Home-Based Cardiac Telemetry Reimbursement Expansion

Medicare, major U.S. commercial insurers, and several EU payers now reimburse 14-day and 30-day patch ECG services, citing up to 30% lower readmission rates compared with traditional telemetry. VitalConnect earmarked its 2025 USD 100 million raise to triple VitalPatch output for Hospital-at-Home contracts. Complementary platforms such as the LEAF Patient Monitoring System, covered under fall-prevention DRGs, illustrate how multiparameter patches can bundle cardiology and safety use-cases. Reimbursement clarity attracts health-system procurement budgets, which favor patches over bulky holter monitors for elderly patients. Expansion is strongest in the United States today, yet Germany, France, and Japan have introduced pilot codes that should unlock medium-term European and Asian volume.

Data-Security and Privacy Compliance Costs

Patches that blur medical-device and consumer-wellness categories face fragmented regulation. HIPAA exempts many direct-to-consumer wearables, while GDPR imposes strict consent, encryption, and data-minimization obligations. Building dual-stack architectures capable of satisfying both frameworks can add 15-20% to R&D budgets for small manufacturers. Only 20 U.S. states have explicit wearable data laws, creating legal uncertainty that drives conservative security investments. Larger incumbents use existing SOC-2 and ISO-27001 programs to spread compliance fixed costs, widening the competitiveness gap.

Other drivers and restraints analyzed in the detailed report include:

1. Ageing Population and Chronic-Care Decentralisation
2. Flexible Biofuel-Cell Power Sources Hit Mass Production
3. Adhesion / Skin-Irritation Failure Rates

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Energy-Harvesting Smart Patches are growing at a 21.8% CAGR, overtaking traditional, battery-powered sensing platforms in demand velocity. The electronic skin patch market size for this sub-category is projected to more than triple between 2025 and 2030 as power-autonomous designs remove both environmental waste and user inconvenience linked to weekly sensor swaps. Sensing and Diagnostic Patches, while mature, still control 46% 2024 revenue and remain essential in regulated care pathways where clinicians prioritize accuracy and established reimbursement. Drug-Delivery Patches keep steady adoption in pain and hormone therapy, but lack the growth inflection energy-harvesting variants enjoy. Cosmetic and Wellness Patches, driven by consumer focus on anti-aging and hydration analytics, form a modest but rising revenue line that attracts beauty majors eager for data-rich personalization.

Recent academic-industry collaboration produced sweat-powered micro-supercapacitors that output 20 mA cm-2 after a six-minute charge, validating real-world readiness beyond lab prototypes. University of Waterloo researchers knit thermoelectric yarns directly into biocompatible substrates, integrating power and sensor arrays without added thickness. Such advances align with OEM roadmaps to re-engineer housings around thinner, more flexible stacks, allowing devices to conform to high-motion anatomical sites like elbows and knees. As IP matures, licensing deals between chipmakers, adhesive formulators, and consumer-health brands should accelerate, further boosting electronic skin patch market penetration in outpatient protocols and lifestyle segments alike.

Cardiovascular Monitoring held a commanding 38.2% electronic skin patch market share in 2024, upheld by payer focus on reducing readmissions through rhythm surveillance. Yet Women's Health and Fertility applications, projected at 19.51% CAGR, now represent the most dynamic vector as long-neglected clinical needs receive venture backing. MIT's portable breast ultrasound patch exemplifies how self-contained imaging can transition from hospitals to living rooms. Fertility-tracking companies leverage hormone-sensing hydrogels for continuous luteinizing hormone readouts, empowering users with cycle predictions more precise than basal-temperature charts.

Pain and Musculoskeletal management harnesses electrical-stimulation patches that gate nerve signals, offering opioid-free analgesia. Diabetes Management remains sizeable due to CGM volume, yet its growth moderates as penetration approaches saturation in insulin-dependent cohorts. Neuro-mental health remains nascent but promising: electrodermal-activity patches, coupled with machine-learning classifiers, screen for anxiety episodes, enabling timely behavioral cues. The diversification across applications reduces revenue cyclicality and underscores the electronic skin patch industry's ability to pivot toward underserved populations.

The Electronic Skin Patches Market Report is Segmented by Product Type (Sensing and Diagnostic Patches, Drug-Delivery Patches, and More), Application (Cardiovascular Monitoring, Drug-Delivery, and More), Technology (Electrochemical Biosensors, MEMS and Microfluidics, and More), Adhesive Material (Silicone-Based, Acrylic-Based, and More), End-User (Hospitals and Clinics, Home Healthcare, and More), and Geography.

Geography Analysis

North America commands 37.9% electronic skin patch market share in 2024, benefited by FDA pathways that brought OTC CGMs to pharmacy shelves, thus expanding unit volumes beyond endocrinology clinics. Hospital-at-Home reimbursement codes convert remote monitoring into predictable revenue streams for providers, sustaining purchase orders even after pandemic peaks. Canada experiments with provincial remote-cardiac programs, while Mexican maquiladoras attract OEM assembly due to tariff-free USMCA logistics, shaving 8-10% off landed costs.

Asia Pacific delivers the fastest 16.5% CAGR, powered by China's Healthy China 2030 blueprint that funds digital-health pilots and by Japan's Silver Economy demand spike. South Korea's ODM fabs tout vertical integration-from flex-PCB etching to sterile packaging-slashing lead times for Western brands entering the region. India's National Digital Health Mission reimburses Bluetooth LE-enabled patches in pilot diabetes programs, albeit with price caps that favor energy-harvesting models over battery-heavy imports.

Europe grows steadily despite GDPR friction: stringent data controls catalyze investments in on-patch encryption ASICs, yielding differentiated products able to command premium ASPs. The bloc's Battery Regulation, effective 2027, pushes manufacturers toward biofuel-cell power, aligning with eco-design incentives. Germany leverages public-private clusters in Baden-Wurttemberg for polymer research, while the U.K. NHS integrates patches into virtual-ward targets aimed at freeing 5,000 acute beds by 2026. Nordic e-prescription networks automatically link CGM data, enabling algorithmic insulin dosing in primary care.

1. Abbott Laboratories
2. DexCom Inc.
3. iRhythm Technologies Inc.
4. VitalConnect Inc.
5. Medtronic plc
6. Insulet Corporation
7. Leaf Healthcare Inc.
8. Sensium Healthcare Ltd.
9. MC10 Inc.
10. Quad Industries SA
11. L-Or-al SA
12. Philips Healthcare
13. GE Healthcare
14. Nemaura Medical
15. VivaLNK
16. Masimo Corporation
17. Blue Spark Technologies
18. G-Tech Medical
19. Omron Healthcare
20. Nutromics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Continuous glucose-monitoring (CGM) patch adoption surge
  • 4.2.2 Home-based cardiac telemetry reimbursement expansion
  • 4.2.3 Ageing population and chronic-care decentralisation
  • 4.2.4 Flexible biofuel-cell power sources hit mass production
  • 4.2.5 Hospital-at-home CPT codes for connected patches
  • 4.2.6 API-level integration with digital-therapeutics platforms
• 4.3 Market Restraints
  • 4.3.1 Data-security and privacy compliance costs
  • 4.3.2 Adhesion / skin-irritation failure rates
  • 4.3.3 Battery-disposal and e-waste regulation pressure
  • 4.3.4 Patch reimbursement gaps in emerging economies
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry
• 4.8 Investment and Funding Trends

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Product Type
  • 5.1.1 Sensing and Diagnostic Patches
  • 5.1.2 Drug-Delivery Patches
  • 5.1.3 Electrical-Stimulation Patches
  • 5.1.4 Cosmetic and Wellness Patches
  • 5.1.5 Energy-Harvesting Smart Patches
• 5.2 By Application
  • 5.2.1 Cardiovascular Monitoring
  • 5.2.2 Diabetes Management
  • 5.2.3 Pain / Musculoskeletal
  • 5.2.4 Infectious-Disease and Fever
  • 5.2.5 Women's Health and Fertility
  • 5.2.6 Neuro and Mental Health
  • 5.2.7 Sports and Fitness
  • 5.2.8 Drug-Delivery
• 5.3 By Technology
  • 5.3.1 Electrochemical Biosensors
  • 5.3.2 Optical / PPG Sensors
  • 5.3.3 MEMS and Microfluidics
  • 5.3.4 RFID / NFC Smart Patches
  • 5.3.5 Energy-Harvesting and Battery-less
• 5.4 By Adhesive Material
  • 5.4.1 Silicone-based
  • 5.4.2 Acrylic-based
  • 5.4.3 Hydrogel-based
  • 5.4.4 Others (PU, Hybrid)
• 5.5 By End-User
  • 5.5.1 Hospitals and Clinics
  • 5.5.2 Home Healthcare
  • 5.5.3 Sports and Fitness Centres
  • 5.5.4 Military and Emergency Services
  • 5.5.5 Cosmetic and Dermatology Clinics
  • 5.5.6 Research Institutions
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 South America
    • 5.6.2.1 Brazil
    • 5.6.2.2 Argentina
    • 5.6.2.3 Rest of South America
  • 5.6.3 Europe
    • 5.6.3.1 Germany
    • 5.6.3.2 United Kingdom
    • 5.6.3.3 France
    • 5.6.3.4 Italy
    • 5.6.3.5 Spain
    • 5.6.3.6 Russia
    • 5.6.3.7 Rest of Europe
  • 5.6.4 Asia Pacific
    • 5.6.4.1 China
    • 5.6.4.2 India
    • 5.6.4.3 Japan
    • 5.6.4.4 South Korea
    • 5.6.4.5 ASEAN
    • 5.6.4.6 Rest of Asia Pacific
  • 5.6.5 Middle East and Africa
    • 5.6.5.1 Middle East
    • 5.6.5.1.1 Saudi Arabia
    • 5.6.5.1.2 UAE
    • 5.6.5.1.3 Turkey
    • 5.6.5.1.4 Rest of Middle East
    • 5.6.5.2 Africa
    • 5.6.5.2.1 South Africa
    • 5.6.5.2.2 Nigeria
    • 5.6.5.2.3 Rest of Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.4.1 Abbott Laboratories
  • 6.4.2 DexCom Inc.
  • 6.4.3 iRhythm Technologies Inc.
  • 6.4.4 VitalConnect Inc.
  • 6.4.5 Medtronic plc
  • 6.4.6 Insulet Corporation
  • 6.4.7 Leaf Healthcare Inc.
  • 6.4.8 Sensium Healthcare Ltd.
  • 6.4.9 MC10 Inc.
  • 6.4.10 Quad Industries SA
  • 6.4.11 L-Or-al SA
  • 6.4.12 Philips Healthcare
  • 6.4.13 GE Healthcare
  • 6.4.14 Nemaura Medical
  • 6.4.15 VivaLNK
  • 6.4.16 Masimo Corporation
  • 6.4.17 Blue Spark Technologies
  • 6.4.18 G-Tech Medical
  • 6.4.19 Omron Healthcare
  • 6.4.20 Nutromics

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-space and Unmet-need Assessment